MSOS: What the Cannabis Rescheduling Shift Means for Investors
Key Takeaways
- Regulatory inflection point: The U.S. Department of Justice finalized the reclassification of medical cannabis from Schedule I to Schedule III in April 2026, removing a decades-long structural barrier and laying groundwork for broader reform.
- Tax relief is the core catalyst: Rescheduling clears the way for relief from IRS Section 280E, which currently bars cannabis operators from deducting ordinary business expenses, potentially lifting net income and free cash flow for MSOS's core holdings.
- Concentrated portfolio exposure: The ETF is heavily weighted toward a handful of multi-state operators, amplifying both upside from policy progress and downside from any regulatory or execution setbacks.
- Institutional participation: A shift in federal status lowers the barrier for institutional capital, banking access, and exchange uplistings, factors that could support valuations and fund inflows over time.
- Upcoming catalysts: Adult-use rescheduling hearings, potential banking reform, exchange uplistings, and quarterly earnings from top operators remain key events to monitor.
- Structural risks persist: State-versus-federal legal gaps, sector volatility, and limited diversification mean the macro outlook for this ETF remains highly event-driven.
Portfolio Exposure and ETF Strategy Overview
The MSOS AdvisorShares Pure US Cannabis ETF is an actively managed fund that seeks to invest at least 80% of its net assets in securities of companies deriving at least half of their net revenue from the U.S. marijuana and hemp industries, or in derivatives with similar economic characteristics. It was the first U.S.-listed ETF offering dedicated, exclusively domestic cannabis exposure and remains the largest fund in the category.
Because many leading U.S. cannabis operators historically traded over-the-counter or on Canadian exchanges, the fund uses total return swaps to gain economic exposure to these companies. Its portfolio is concentrated among major multi-state operators (MSOs) — companies that cultivate, process, and sell cannabis across multiple U.S. states — including Curaleaf Holdings, Green Thumb Industries, Trulieve Cannabis, Glass House Brands, Verano Holdings, Cresco Labs, and TerrAscend. This concentration means the fund's future performance potential is tightly linked to the profitability, balance sheets, and strategic execution of a small group of operators rather than to broad equity market trends.
The net expense ratio is roughly 0.78%, and the fund is non-diversified, meaning position weights can reach levels that meaningfully influence returns. As a result, portfolio exposure here functions less like a diversified sector bet and more like a targeted wager on U.S. cannabis operators' ability to convert regulatory tailwinds into sustained earnings growth. I also checked this using Tickeron’s AI Screener to see how the holdings stack up against peers.
Major Catalysts Ahead
Several forward-looking developments could materially shape this ETF's trajectory:
- Section 280E tax relief: Under Schedule I status, cannabis businesses have been unable to deduct ordinary expenses such as wages and rent, pushing effective tax rates far above typical corporate levels. Relief from 280E could boost earnings before interest, taxes, depreciation, and amortization (EBITDA) margins by double-digit percentage points for leading operators, directly improving their fundamentals.
- Adult-use rescheduling and DEA proceedings: While medical cannabis rescheduling is finalized, hearings around broader adult-use rescheduling and related Drug Enforcement Administration (DEA) processes remain in motion. Progress or delays here could drive sharp sentiment shifts.
- Banking and capital access: Long-pending banking reform, sometimes referred to as the SAFER Banking Act, could allow operators to access traditional lending, lower financing costs, and expand institutional ownership — a structural catalyst for sector valuations.
- Exchange uplistings: Several top holdings have pursued or completed moves to major U.S. exchanges. Uplisting can broaden the investor base, improve liquidity, and draw passive and institutional capital into the sector.
- Earnings from core holdings: Quarterly results from Curaleaf, Trulieve, Green Thumb, and others will reveal whether tax relief is translating into actual margin expansion and free cash flow, or whether oversupply and price competition continue to pressure profitability.
- Fund flows: The ETF has historically seen inflows spike around regulatory headlines. Sustained, fundamentals-driven inflows — rather than event-driven bursts — would signal a more durable shift in investor positioning.
Sector, Index, and Macroeconomic Outlook
The macro outlook for this ETF hinges less on traditional interest-rate cycles than on policy, consumer demand, and capital availability. Still, broader conditions matter. Elevated borrowing costs have historically constrained capital-intensive cannabis operators, so a lower-rate environment could ease financing pressure and support expansion. At the same time, cannabis demand is tied to consumer discretionary spending, making the sector sensitive to inflation trends and economic growth expectations.
The U.S. legal cannabis market continues to expand as more states legalize medical or adult-use sales, with a large majority of Americans living in states where cannabis is legal in some form. Yet the industry has also grappled with oversupply, price compression, and margin pressure in several mature markets. The equity market backdrop for the sector remains volatile, with valuations well below historical peaks despite improving fundamentals — a gap that could narrow if institutional capital re-enters. From what I see, this dynamic keeps the focus squarely on regulatory milestones rather than broader market cycles.
Long-Term Outlook and Structural Trends
Over a longer horizon, several structural themes could define this ETF's trajectory. The most consequential is the normalization of cannabis as a regulated U.S. industry. Finalized medical rescheduling, combined with potential adult-use reform and banking access, would gradually shift the sector from a speculative, policy-dependent trade toward a fundamentals-driven growth story. Removal of punitive tax treatment is central to that transition, as it could unlock sustained profitability for operators that have long been profitable on an operational basis but burdened at the tax level.
Demographic and social trends are also supportive. Public acceptance of cannabis remains high, and legal access continues to broaden across states. Meanwhile, institutional adoption — from exchange listings to expanded research coverage and larger capital pools — could improve liquidity and reduce the sector's historical discount. Market structure changes, including consolidation among MSOs and the separation of medical and adult-use businesses, may also reshape competitive dynamics.
At the same time, the long-term outlook carries meaningful structural risks. Federal legalization remains incomplete, interstate commerce is still restricted, and operators must navigate a patchwork of state regulations. Concentrated portfolio exposure amplifies the impact of any single operator's missteps. Investors weighing this ETF's future should therefore balance the scale of the regulatory opportunity against the sector's inherent volatility and the fund's limited diversification. I'm watching this closely as more data emerges on how these themes play out.
Using Tickeron’s Trend Prediction Engine for Event-Driven Sectors
In my analysis of event-driven areas like U.S. cannabis, Tickeron’s AI Trend Prediction Engine provides a useful layer for spotting potential bullish, bearish, or sideways moves over the near term. It helps evaluate momentum and breakouts with historical context, which I find complements fundamental policy tracking when assessing instruments like MSOS.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for MSOS turns negative, indicating new downward trend
MSOS saw its Momentum Indicator move below the 0 level on September 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 75 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for MSOS turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 34 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
MSOS moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MSOS crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MSOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MSOS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MSOS's RSI Indicator exited the oversold zone, 31 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 66 of 67 cases where MSOS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +8.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where MSOS advanced for three days, in 195 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
MSOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category MiscellaneousSector
Advertisement